AcquisitionVimian's acquisition of AllAccem Inc., a company with a high EBITDA margin and strong double-digit growth, enhances its MedTech portfolio and market leadership in veterinary dental care.
Financial PerformanceVimian's 1Q25 profitability surpassed expectations, with net sales increasing by 18% year-over-year, driven by robust growth in Specialty Pharma, Veterinary Services, and Diagnostics.
Stock Market ListingVimian's approval to list on the Nasdaq Stockholm Main Market in the Large Cap segment is expected to enhance share liquidity and attract a broader investor base.